RITUXAN, along with CHOP chemotherapy, can be used as initial treatment for DLBCL. The goal in using this combination of drugs is to improve your chances of survival.
In one study, patients who received RITUXAN plus CHOP chemotherapy spent an average of 2.9 years without their cancer advancing or the need for a change in therapy, compared with an average of 1.1 years for patients who received CHOP chemotherapy by itself. Adding RITUXAN to CHOP chemotherapy as initial therapy reduced the risk of death by 32% compared to receiving CHOP chemotherapy alone. These results were from a clinical trial and may not be the same as what you experience.
You will have up to 8 cycles, or rounds, of treatment. Each cycle will last 21 days. Treatment occurs on the first day of each cycle and is followed by 20 days of rest and recovery. This means that most people will complete their treatment in about 6 months.
PATIENTS MAY RECEIVE FEWER THAN 8 CYCLES OF RITUXAN IN COMBINATION WITH CHEMOTHERAPY.
Severe side effects reported more often in patients receiving RITUXAN and CHOP chemotherapy vs. CHOP chemotherapy alone were decreased blood cell counts, including decreases in white blood cells, red blood cells, and platelets; lung disorder; and viral infections. In studies of elderly patients, the most common severe side effects reported more often in patients receiving RITUXAN and CHOP chemotherapy vs. CHOP chemotherapy alone were fever, lung disorder, heart disorder, and chills.
RITUXAN is available by prescription only.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.